Novo Nordisk Raises 2026 Guidance as Oral Wegovy Sales Surge

Key Facts

1Novo Nordisk management raised 2026 guidance citing stronger-than-expected GLP-1 sales and international growth.

2Oral Wegovy recorded over 3 million U.S. prescriptions in five months, with 80% coming from GLP-1–naïve patients.

Reflecting the rapid expansion of the global obesity treatment market, Novo Nordisk management has raised its financial guidance for 2026. This upgrade is driven by stronger-than-expected sales of GLP-1 therapies and robust international growth. According to reports, the oral version of Wegovy recorded over 3 million U.S. prescriptions within just five months, with 80% of those coming from patients who were previously GLP-1–naïve.

This strong performance comes amid intensifying competition with Eli Lilly, as both firms dominate a weight-loss market projected by Goldman Sachs to reach $100 billion by the end of the decade. Compared to previous quarters, the data indicates sustained growth in market share despite ongoing supply chain challenges. Per market data, the success of the oral formulation provides a strategic advantage in patient convenience over traditional injectable treatments.

NVO stock stood at $50.43 (at close July 02, 2026), having reached a session high of $50.90. Investors should watch for upcoming regulatory updates or new clinical data from peers, while also keeping an eye on broader catalysts such as the China Manufacturing PMI due on June 30, which could impact global healthcare sector sentiment.